Briefing
Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker
AACR 2025 abstract CT132 of NCT03575611: median PFS 18 months and median STFS 34 months in 121 patients; baseline ctDNA MRD+ in 56%, with shorter STFS (HR 2.9, 27 vs 54 months); 31% of baseline-MRD+ patients converted to MRD– at 3 months, and 3-month MRD+ was associated with shorter STFS (HR 4.3).
- n: 121 patients enrolled July 2018–May 2023 (NCT03575611)
- Assay: Individualized ctDNA panels (Myriad Genetics) from tumor whole-genome sequencing; MRD+ if ctDNA detected